Using Lithium in Children and Adolescents with Bipolar Disorder: Efficacy, Tolerability, and Practical Considerations
- 166 Downloads
Lithium has been an intriguing treatment option in psychiatry for over a century. While seemingly just a simple elemental compound, it has powerful treatment effects for both depression and bipolar disorder. The evidence base for treatment of pediatric bipolar disorder is relatively small, but, in recent years, additional clinical trial data have enabled lithium to re-emerge as a valuable and, in many cases, preferred treatment. Pharmacologically, lithium is complex, with varied effects at both intracellular and extracellular levels. As a treatment for bipolar disorder in pediatrics, lithium is challenging, given its narrow therapeutic window and myriad of potential side effects. However, the efficacy of lithium continues to match that of newer pharmacologic agents, and its tolerability has been shown to be comparable with more commonly prescribed medications. Lithium is still one of few drugs that have been proven to reduce the risk of suicidality, and it may have utility in illnesses beyond affective disorders. Practically, as a primary agent or as an adjunct, lithium continues to claim a rightful place in the treatment armamentarium of child psychiatry. New dosing paradigms have improved tolerability and reduced potential side effects. Recent evidence affirms that lithium is effective for pediatric bipolar disorder in multiple phases of the illness.
Both authors participated in the writing, editing, and approval of this manuscript and had full control of content throughout development.
Compliance with Ethical Standards
No sources of funding were used to conduct this study or prepare this manuscript.
Conflict of interest
Dr. Salpekar is a past educational consultant for Sunovion, his institution receives research funding from Lundbeck, and he serves as a Data and Safety Monitoring Board chair for the National Institute of Mental Health. Dr. Grant has no conflicts of interest.
- 3.Carlson GA, Glovinsky I. The concept of bipolar disorder in children: a history of the bipolar controversy. Child Adolesc Psychiatr Clin N Am. 2009;18(2):257–71, vii. https://doi.org/10.1016/j.chc.2008.11.003.
- 5.McClellan J, Kowatch R, Findling RL, Work Group on Quality I. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(1):107–25. https://doi.org/10.1097/01.chi.0000242240.69678.c4.CrossRefPubMedGoogle Scholar
- 7.Kessler RC, Avenevoli S, Green J, Gruber MJ, Guyer M, He Y, et al. National comorbidity survey replication adolescent supplement (NCS-A): III. Concordance of DSM-IV/CIDI diagnoses with clinical reassessments. J Am Acad Child Adolesc Psychiatry. 2009;48(4):386–99. https://doi.org/10.1097/CHI.0b013e31819a1cbc.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Hauser M, Galling B, Correll CU. Suicidal ideation and suicide attempts in children and adolescents with bipolar disorder: a systematic review of prevalence and incidence rates, correlates, and targeted interventions. Bipolar Disord. 2013;15(5):507–23. https://doi.org/10.1111/bdi.12094.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Landersdorfer CB, Findling RL, Frazier JA, Kafantaris V, Kirkpatrick CM. Lithium in paediatric patients with bipolar disorder: implications for selection of dosage regimens via population pharmacokinetics/pharmacodynamics. Clin Pharmacokinet. 2017;56(1):77–90. https://doi.org/10.1007/s40262-016-0430-3.CrossRefPubMedGoogle Scholar
- 17.Findling RL, Kafantaris V, Pavuluri M, McNamara NK, McClellan J, Frazier JA, et al. Dosing strategies for lithium monotherapy in children and adolescents with bipolar I disorder. J Child Adolesc Psychopharmacol. 2011;21(3):195–205. https://doi.org/10.1089/cap.2010.0084.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Selle V, Schalkwijk S, Vazquez GH, Baldessarini RJ. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry. 2014;47(2):43–52. https://doi.org/10.1055/s-0033-1363258.CrossRefPubMedGoogle Scholar
- 29.Wingard L, Boden R, Brandt L, Tiihonen J, Tanskanen A, Kieler H, et al. Reducing the rehospitalization risk after a manic episode: a population based cohort study of lithium, valproate, olanzapine, quetiapine and aripiprazole in monotherapy and combinations. J Affect Disord. 2017;217:16–23. https://doi.org/10.1016/j.jad.2017.03.054.CrossRefPubMedGoogle Scholar
- 31.Geller B, Luby JL, Joshi P, Wagner KD, Emslie G, Walkup JT, et al. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry. 2012;69(5):515–28. https://doi.org/10.1001/archgenpsychiatry.2011.1508.CrossRefPubMedGoogle Scholar
- 32.Salpekar JA, Joshi PT, Axelson DA, Reinblatt SP, Yenokyan G, Sanyal A, et al. Depression and suicidality outcomes in the treatment of early age mania study. J Am Acad Child Adolesc Psychiatry. 2015;54(12):999–1007 e4. https://doi.org/10.1016/j.jaac.2015.09.016.
- 34.Kafantaris V, Coletti D, Dicker R, Padula G, Kane JM. Lithium treatment of acute mania in adolescents: a large open trial. J Am Acad Child Adolesc Psychiatry. 2003;42(9):1038–45. https://doi.org/10.1097/01.CHI.0000070247.24125.24.CrossRefPubMedGoogle Scholar
- 35.Kafantaris V, Coletti DJ, Dicker R, Padula G, Pleak RR, Alvir JM. Lithium treatment of acute mania in adolescents: a placebo-controlled discontinuation study. J Am Acad Child Adolesc Psychiatry. 2004;43(8):984–93. https://doi.org/10.1097/01.chi.0000129223.89433.74.CrossRefPubMedGoogle Scholar
- 36.Patel NC, DelBello MP, Bryan HS, Adler CM, Kowatch RA, Stanford K, et al. Open-label lithium for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry. 2006;45(3):289–97. https://doi.org/10.1097/01.chi.0000194569.70912.a7.CrossRefPubMedGoogle Scholar
- 37.Findling RL, McNamara NK, Gracious BL, Youngstrom EA, Stansbrey RJ, Reed MD, et al. Combination lithium and divalproex sodium in pediatric bipolarity. J Am Acad Child Adolesc Psychiatry. 2003;42(8):895–901. https://doi.org/10.1097/01.CHI.0000046893.27264.53.CrossRefPubMedGoogle Scholar
- 39.Pavuluri MN, Henry DB, Carbray JA, Sampson GA, Naylor MW, Janicak PG. A one-year open-label trial of risperidone augmentation in lithium nonresponder youth with preschool-onset bipolar disorder. J Child Adolesc Psychopharmacol. 2006;16(3):336–50. https://doi.org/10.1089/cap.2006.16.336.CrossRefPubMedGoogle Scholar
- 40.Calabrese JR, Shelton MD, Rapport DJ, Youngstrom EA, Jackson K, Bilali S, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry. 2005;162(11):2152–61. https://doi.org/10.1176/appi.ajp.162.11.2152.CrossRefPubMedGoogle Scholar
- 43.Geller B, Cooper TB, Sun K, Zimerman B, Frazier J, Williams M, et al. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry. 1998;37(2):171–8. https://doi.org/10.1097/00004583-199802000-00009.CrossRefPubMedGoogle Scholar
- 53.Findling RL, Nyilas M, Forbes RA, McQuade RD, Jin N, Iwamoto T, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2009;70(10):1441–51. https://doi.org/10.4088/JCP.09m05164yel.CrossRefPubMedGoogle Scholar
- 56.Pathak S, Findling RL, Earley WR, Acevedo LD, Stankowski J, Delbello MP. Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial. J Clin Psychiatry. 2013;74(1):e100–9. https://doi.org/10.4088/JCP.11m07424.CrossRefPubMedGoogle Scholar
- 57.Haas M, Delbello MP, Pandina G, Kushner S, Van Hove I, Augustyns I, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2009;11(7):687–700. https://doi.org/10.1111/j.1399-5618.2009.00750.x.CrossRefPubMedGoogle Scholar
- 58.Detke HC, DelBello MP, Landry J, Usher RW. Olanzapine/Fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2015;54(3):217–24. https://doi.org/10.1016/j.jaac.2014.12.012.CrossRefPubMedGoogle Scholar
- 63.Hou L, Heilbronner U, Degenhardt F, Adli M, Akiyama K, Akula N, et al. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet. 2016;387(10023):1085–93. https://doi.org/10.1016/S0140-6736(16)00143-4.CrossRefPubMedPubMedCentralGoogle Scholar
- 64.Duffy A, Patten S, Goodday S, Weir A, Heffer N, Cipriani A. Efficacy and tolerability of lithium in treating acute mania in youth with bipolar disorder: protocol for a systematic review. Int J Bipolar Disord. 2017;5(1):22. https://doi.org/10.1186/s40345-017-0092-6.CrossRefPubMedPubMedCentralGoogle Scholar